See more : Insigma Technology Co., Ltd. (600797.SS) Income Statement Analysis – Financial Results
Complete financial analysis of Salarius Pharmaceuticals, Inc. (SLRX) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Salarius Pharmaceuticals, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- Utoc Corporation (9358.T) Income Statement Analysis – Financial Results
- Bookook Steel Co., Ltd. (026940.KS) Income Statement Analysis – Financial Results
- Matchaah Holdings, Inc. (MCHA) Income Statement Analysis – Financial Results
- LAUNXP Biomedical Co., Ltd (6876.TWO) Income Statement Analysis – Financial Results
- PesoRama Inc. (PESO.V) Income Statement Analysis – Financial Results
Salarius Pharmaceuticals, Inc. (SLRX)
About Salarius Pharmaceuticals, Inc.
Salarius Pharmaceuticals, Inc., a clinical-stage biotechnology company, focuses on developing epigenetic-based cancer treatments. Its lead candidate is Seclidemstat (SP-2577), a small molecular inhibitor which is in Phase I/II clinical trial for the treatment of advanced solid tumors, as well as Ewing sarcoma. The company also offers SP-3164, a small molecular protein degrader for the treatment of hematological and solid tumors. It has a strategic partnership with The University of Utah Research Foundation for the exclusive license with respect to patent rights protecting SP-2577 and related compounds; HLB Life Sciences to develop, produce, manufacture, use, and sell the drug in South Korea; and Cancer Prevention and Research Institute of Texas for product development activities, as well as a research partnership with the Cancer Epigenetics Institute at Fox Chase Cancer Center to identify new indications and biomarkers for SP-2577. The company is headquartered in Houston, Texas.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 1.84M | 5.23M | 3.47M | 838.00K | 1.28M | 1.01M | 0.00 |
| Cost of Revenue | 10.05K | 6.68K | 19.18K | 6.91K | 4.02K | 431.00K | 507.00K | 663.00K | 49.88K |
| Gross Profit | -10.05K | -6.68K | 1.82M | 5.23M | 3.46M | 407.00K | 768.00K | 348.00K | -49.88K |
| Gross Profit Ratio | 0.00% | 0.00% | 98.96% | 99.87% | 99.88% | 48.57% | 60.24% | 34.42% | 0.00% |
| Research & Development | 7.17K | 15.84M | 8.55M | 6.91M | 4.02M | 11.91M | 16.99M | 20.38M | 12.75M |
| General & Administrative | 5.72K | 7.14M | 6.10M | 6.11M | 7.71M | 2.35M | 1.37M | 797.49K | 0.00 |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 8.22M | 17.14M | 19.06M | 0.00 |
| SG&A | 5.72K | 7.14M | 6.10M | 6.11M | 7.71M | 10.57M | 18.50M | 19.86M | 16.46M |
| Other Expenses | 0.00 | 8.87M | -4.00 | -178.59K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Expenses | 12.89K | 22.98M | 14.65M | 12.84M | 11.73M | 22.48M | 35.49M | 40.23M | 29.21M |
| Cost & Expenses | 12.89K | 22.98M | 14.65M | 12.84M | 11.73M | 22.91M | 36.00M | 40.90M | 29.21M |
| Interest Income | 352.25K | 218.73 | 0.00 | 0.00 | 15.65K | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Expense | 0.00 | 0.00 | 0.00 | 3.05K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | 10.05K | 6.68K | 19.18K | 18.06K | 16.93K | 16.95K | 324.55K | 277.23K | 49.88K |
| EBITDA | -12.88K | -31.60M | -12.75M | -7.33M | -6.92M | -22.07M | -34.11M | -39.89M | -29.09M |
| EBITDA Ratio | 0.00% | 0.00% | -698.70% | -149.97% | -272.69% | -2,634.13% | -2,723.61% | -3,945.20% | 0.00% |
| Operating Income | -12.89K | -31.84M | -12.81M | -7.79M | -9.58M | -22.07M | -34.73M | -39.89M | -29.21M |
| Operating Income Ratio | 0.00% | 0.00% | -696.27% | -148.78% | -276.37% | -2,634.13% | -2,723.61% | -3,945.20% | 0.00% |
| Total Other Income/Expenses | 352.25 | 233.18K | 44.69K | 434.09K | 1.33M | 152.01K | 291.96K | 393.11K | 72.00K |
| Income Before Tax | -12.54K | -31.61M | -12.77M | -7.35M | -6.94M | -21.92M | -34.43M | -39.49M | -29.14M |
| Income Before Tax Ratio | 0.00% | 0.00% | -693.84% | -140.49% | -200.23% | -2,615.99% | -2,700.71% | -3,906.33% | 0.00% |
| Income Tax Expense | 0.00 | -233.18K | -63.88K | -255.50K | -1.33M | 152.01K | -324.58K | -277.12K | -49.85K |
| Net Income | -12.54K | -31.37M | -12.70M | -7.10M | -5.61M | -21.92M | -34.43M | -39.49M | -29.14M |
| Net Income Ratio | 0.00% | 0.00% | -690.37% | -135.61% | -161.88% | -2,615.99% | -2,700.71% | -3,906.33% | 0.00% |
| EPS | 0.00 | -14.77 | -7.68 | -11.39 | -42.90 | -760.47 | -1.25K | -1.52K | -1.30K |
| EPS Diluted | 0.00 | -14.77 | -7.68 | -11.39 | -42.90 | -760.47 | -1.25K | -1.52K | -1.30K |
| Weighted Avg Shares Out | 3.26M | 2.12M | 1.65M | 623.14K | 130.75K | 28.83K | 27.62K | 25.97K | 22.45K |
| Weighted Avg Shares Out (Dil) | 3.26M | 2.12M | 1.65M | 623.14K | 130.75K | 28.83K | 27.62K | 25.97K | 22.45K |
Salarius Pharmaceuticals and Nationwide Children's Hospital Announce Poster Presentation at the 2021 AACR-NCI-EORTC Virtual International Conference on Molecular Targets and Cancer Therapeutics
HOUSTON, Sept. 30, 2021 (GLOBE NEWSWIRE) -- Salarius Pharmaceuticals, Inc. (Nasdaq: SLRX), a clinical-stage biopharmaceutical company developing potential new medicines for patients with pediatric cancers, solid tumors, and other cancers, and Nationwide Children's Hospital disclosed today that an abstract has...
Salarius Pharmaceuticals Receives $2.7 Million in Payment from the Cancer Prevention and Research Institute of Texas
HOUSTON, Sept. 28, 2021 (GLOBE NEWSWIRE) -- Salarius Pharmaceuticals, Inc. (Nasdaq: SLRX), a clinical-stage biopharmaceutical company developing potential new medicines for patients with sarcomas, pediatric cancers, and other hematologic and solid tumors, today announced the receipt of a $2.7 million...
Salarius Pharmaceuticals and Fox Chase Cancer Center Launch Research Partnership
HOUSTON, Sept. 22, 2021 (GLOBE NEWSWIRE) -- Salarius Pharmaceuticals Inc. (Nasdaq: SLRX), a clinical-stage biopharmaceutical company developing potential new medicines for patients with sarcomas, pediatric cancers, and other hematologic and solid tumors, today announced a research partnership with the Cancer...
Salarius Pharmaceuticals Added to FTSE Global Micro Cap Index
HOUSTON, Sept. 20, 2021 (GLOBE NEWSWIRE) -- Salarius Pharmaceuticals, Inc. (Nasdaq: SLRX), a clinical-stage biopharmaceutical company developing potential new medicines for patients with sarcomas, pediatric cancers, and other hematologic and solid tumors, today announced its inclusion in the FTSE Global...
Salarius Pharmaceuticals to Present at the Virtual Life Science Investor Forum
HOUSTON, Sept. 15, 2021 (GLOBE NEWSWIRE) -- Salarius Pharmaceuticals, Inc. (Nasdaq: SLRX), a clinical-stage biopharmaceutical company developing potential new medicines for patients with sarcomas, pediatric cancers, and other hematologic and solid tumors, announced today that David Arthur, Chief Executive Officer,...
Salarius Pharmaceuticals to Present at the Virtual H.C. Wainwright 23rd Annual Global Investment Conference
HOUSTON, Sept. 08, 2021 (GLOBE NEWSWIRE) -- Salarius Pharmaceuticals, Inc. (Nasdaq: SLRX), a clinical-stage biopharmaceutical company developing potential new medicines for patients with sarcomas, pediatric cancers, and other hematologic and solid tumors, announced today that David Arthur, Chief Executive Officer,...
Salarius Pharmaceuticals to Present at the Virtual Diamond Equity Research Emerging Growth Invitational
HOUSTON, Aug. 12, 2021 (GLOBE NEWSWIRE) -- Salarius Pharmaceuticals, Inc. (Nasdaq: SLRX), a clinical-stage biopharmaceutical company developing potential new medicines for patients with sarcomas, pediatric cancers, and other hematologic and solid tumors, announced today that David Arthur, Chief Executive Officer,...
Salarius Pharmaceuticals, Inc. (SLRX) CEO David Arthur on Q2 2021 Results - Earnings Call Transcript
Salarius Pharmaceuticals, Inc. (SLRX) CEO David Arthur on Q2 2021 Results - Earnings Call Transcript
Salarius Pharmaceuticals Reports Second Quarter 2021 Financial Results and Highlights Recent Company Progress
Clinical Trial in Hematologic Cancers Initiated and Initial Patients Enrolled in Expanded Sarcoma Clinical Trial; Multiple Potential Data Readouts Expected in 2021 and 2022
Salarius Pharmaceuticals to Report Second Quarter 2021 Financial Results
Conference Call and Live Audio Webcast Scheduled for Thursday, August 5, 2021, 10:00 a.m. ET Conference Call and Live Audio Webcast Scheduled for Thursday, August 5, 2021, 10:00 a.m. ET
Source: https://incomestatements.info
Category: Stock Reports